Choroideremia
28
3
5
16
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.1%
2 terminated out of 28 trials
88.9%
+2.4% vs benchmark
7%
2 trials in Phase 3/4
25%
4 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (28)
High Resolution Retinal Imaging
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
Inherited Retinal Degenerative Disease Registry
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Longitudinal Study of a Bionic Eye
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study
Natural History of the Progression of Choroideremia Study
An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia
Structural and Functional Characterization of Rare Ocular Diseases
"Natural History" Study of Choroideremia
A Study to Assess Choroideremia (CHM) Health Outcomes
Natural Disease Progression in Participants With Choroideremia
Study of a Suprachoroidal Retinal Prosthesis
REP1 Gene Replacement Therapy for Choroideremia